Tesamorelin vs Sermorelin: Which GHRH to Pick, and Why Never Both

Tesamorelin and sermorelin are both synthetic analogs of growth hormone releasing hormone. Both bind the GHRH receptor on pituitary somatotrophs, both amplify pulsatile GH release, and both are dosed at night to ride the body's own largest GH pulse, which occurs in early sleep and is GHRH-driven (Dimaraki et al., 2003, PMID 12670836).

Because they act on the same receptor, they are alternatives rather than partners. Stacking two GHRH analogs adds more ligand competing for a receptor pool that one agent is already stimulating past physiological levels. There is no human data showing benefit from combining two GHRH analogs. If you want to add a second mechanism, the evidence supports pairing one GHRH analog with a ghrelin-receptor agonist such as ipamorelin, which works through a pharmacologically distinct pathway (Bowers et al., 1990, PMID 2108187).

Tesamorelin is the full 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoyl modification that slows DPP-IV cleavage and extends its effective activity. It is FDA-approved (Egrifta, 2010) for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy, and it carries the largest controlled human trial program of any GHRH analog.

Sermorelin is GHRH(1-29), the shortest fragment that retains full biological activity, with a plasma half-life of roughly 11 to 12 minutes. It was marketed as Geref and used both therapeutically in paediatric GH deficiency and diagnostically as a GH stimulation test. The manufacturer voluntarily withdrew it from the US market in November 2002 for commercial reasons, not safety or efficacy failures. That distinction matters, but so does the consequence: sermorelin is not a currently marketed FDA-approved drug, and what is sold under that name today is compounded or grey market.

Structure and half-life:

• Tesamorelin: full GHRH(1-44) with a trans-3-hexenoic acid conjugate protecting the N-terminus from DPP-IV degradation, giving a longer effective duration
• Sermorelin: truncated GHRH(1-29), unmodified, plasma half-life approximately 11 to 12 minutes, producing a short sharp pulse close to native GHRH kinetics

Regulatory status:

• Tesamorelin: FDA-approved June 2010 for HIV-associated lipodystrophy, reformulated as Egrifta SV in 2019, with prescribing information, contraindications and post-marketing pharmacovigilance
• Sermorelin: branded product (Geref) voluntarily withdrawn from the US market in November 2002 for commercial reasons; no currently approved commercial product; all current supply is compounded or research-chemical grade

Evidence base:

• Tesamorelin: Phase 3 program in 806 patients over 26 to 52 weeks (Falutz et al., 2010, PMID 20554713), plus the pivotal 412-patient NEJM trial (Falutz et al., 2007, PMID 18057338), plus a later randomised trial showing reduced liver fat and limited fibrosis progression (Stanley et al., 2019, PMID 31611038)
• Sermorelin: decades of clinical use in paediatric GH deficiency and as a diagnostic agent, so its pharmacology is well characterised, but there is no modern controlled trial of sermorelin for body composition, sleep or recovery in healthy adults

Documented body composition effect:

• Tesamorelin: visceral adipose tissue reduced 15.4 percentage points more than placebo at 26 weeks, durable at 52 weeks; triglycerides fell 48 mg/dL at 52 weeks; IGF-1 rose 108 ng/mL above placebo
• Sermorelin: no controlled body composition data in adults; effects are extrapolated from the shared GHRH mechanism

The sleep and recovery claim:

• Sermorelin is conventionally recommended when sleep and recovery matter more than fat loss. Be aware this preference rests on convention, mechanism and user report rather than dedicated trial evidence. No solid RCT establishes a sleep-quality advantage for sermorelin over tesamorelin, and the same caveat applies to tesamorelin's own commonly claimed sleep benefits.

Glucose:

• Tesamorelin: no statistically significant change in fasting glucose or HbA1c across 806 patients over 52 weeks
• Sermorelin: expected to share the glucose-neutral profile of pulsatile GHRH stimulation, but without controlled confirmation

Cost:

• Tesamorelin: brand pricing runs USD $2,000+ per month; grey market supply exists at far lower cost with the usual identity and purity caveats
• Sermorelin: compounded pricing is typically a fraction of brand tesamorelin, which is much of why it remains popular

Choose tesamorelin if:

• Visceral fat is the specific target. This is the only GHRH analog with a directly measured visceral fat endpoint in a large controlled trial
• Evidence quality is what you are paying for, and you want the compound with real Phase 3 data behind it
• You have hepatic steatosis, whether from metabolic syndrome or from oral AAS use, since the liver fat data is tesamorelin's
• You have access to pharmaceutical-grade product through a prescription
• You prefer a single daily injection with a longer effective duration

Choose sermorelin if:

• Cost is the binding constraint
• You want a short, sharp, near-physiological GHRH pulse rather than extended stimulation, particularly if you are timing it deliberately alongside a GHRP
• General GH-axis support rather than documented visceral fat reduction is the goal
• You accept that you are using a compounded version of a drug that no longer has a marketed approved form

Never choose both. They are the same mechanism. If one GHRH analog is not producing the result you want, the answer is to reconsider dose, timing, or whether the GH axis is the right target at all, not to add a second molecule competing for the same receptor. If you want to amplify the pulse, add ipamorelin, which engages a genuinely different receptor.